What if we could slow the progress of Alzheimer’s disease?

Centre for Imaging Technology Commercialization - CIMTEC (CECR)


The challenge: KalGene Pharmaceuticals Inc. and the National Research Council discovered how to deliver drugs past the blood-brain barrier – a critical obstacle to treating Alzheimer’s and other neurological diseases. Early patient studies showed significant benefits. But KalGene and the NRC needed an experienced partner to accelerate this breakthrough from therapeutic concept to a validated preclinical drug.

The response: Under a multi-year agreement, KalGene is benefiting from CIMTEC’s extensive project and clinical study management services as well as its close connections to world-leading research labs and scientists across Canada. CIMTEC’s brain imaging services and analysis also provided quantitative evidence of the effectiveness of KalGene’s therapy. The centre is currently helping KalGene manage a larger clinical trial with patients, which is expected to get underway in 2017 at the Montreal Neurological Institute and Hospital.

CIMTEC is an ideal example of a commercialization centre fulfilling its mandate. CIMTEC’s team was able to understand where we are coming from, what we require and how they could apply their significant knowledge and expertise toward our success. Dr. T. Nathan Yoganathan, President and Chief Science Officer, KalGene Pharmaceuticals, Inc.